MeVis Medical Solutions (M3V) AI Stock Analysis

• Market Cap: €45.14M
• Dividend Yield: 3.83%
• Average Volume (3M): 34.00
• Price to Earnings (P/E): 10.5
• Beta (1Y): 0.09
• Revenue Growth: -5.72%
• EPS Growth: -25.19%
• Country: DE
• Employees: 100
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 1.32
• Shares Outstanding: 1,820,000
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 34
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 80 Outperform
• Price Target: ―

MeVis Medical Solutions is a financially robust company with strong profitability and a stable balance sheet, reflected in its financial performance score. The stock's positive technical indicators and low volatility further enhance its attractiveness. Valuation metrics suggest potential undervaluation, with a solid dividend yield providing additional appeal. However, challenges in net income efficiency and cash flow generation highlight areas for improvement. Overall, the stock presents a compelling investment opportunity with moderate risks.

MeVis Medical Solutions Business Overview & Revenue Model

Company Description

MeVis Medical Solutions AG (M3V) is a company specializing in the development and marketing of innovative software solutions for the analysis and processing of medical imaging data. Operating primarily in the healthcare and medical technology sectors, the company's core products are designed to enhance diagnostic processes, particularly in radiology, by improving image-based diagnosis and therapy planning.

How the Company Makes Money

MeVis Medical Solutions generates revenue through the sale and licensing of its proprietary software solutions to healthcare providers, hospitals, and medical research facilities. The company also offers maintenance and support services, which provide a recurring revenue stream. Additionally, MeVis partners with major medical device manufacturers to integrate its software into imaging systems, earning revenue from these strategic collaborations. The company benefits from long-term contracts and partnerships with leading healthcare organizations, ensuring a steady flow of income.

MeVis Medical Solutions Financial Statement Overview

Summary

MeVis Medical Solutions exhibits strong profitability and a robust balance sheet with no debt, which is a significant strength. However, declining net profit margins and cash flow metrics suggest potential areas for improvement. Stability in revenue and effective cost management are positives, but the company should focus on enhancing net income efficiency and cash flow generation to maintain its financial health.

Income Statement

MeVis Medical Solutions shows a solid gross profit margin of approximately 97% over the years, indicating strong profitability. However, the net profit margin has seen a decline from 43.5% in 2019 to 26.9% in 2023, which may suggest challenges in maintaining net profitability. Revenue has been relatively stable with a slight decrease in the most recent year. The consistency in EBITDA margins above 28% signals effective operational management.

Balance Sheet

The company maintains a strong balance sheet with zero debt, resulting in a commendable debt-to-equity ratio. The equity ratio remains stable at around 64%, reflecting financial stability. However, the return on equity has decreased from 45.3% in 2019 to 25.6% in 2023, indicating reduced efficiency in generating returns from equity. Strong cash reserves further bolster the company's financial position.

Cash Flow

Free cash flow has generally been positive, with a notable growth rate in earlier years. However, recent declines in operating cash flow and free cash flow are concerning. The ratio of operating cash flow to net income has decreased, reflecting potential challenges in cash generation. Despite this, the company demonstrates a capability to sustain free cash flow relative to net income.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	16.97M	17.34M	18.76M	16.21M	17.13M
Gross Profit	16.48M	7.00M	18.02M	15.78M	16.50M
EBITDA	4.82M	5.17M	7.97M	5.38M	5.97M
Net Income	4.56M	4.92M	7.79M	4.55M	5.70M
Balance Sheet
Total Assets	26.48M	28.05M	31.20M	27.53M	27.79M
Cash, Cash Equivalents and Short-Term Investments	6.53M	7.74M	9.32M	7.62M	3.95M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	8.66M	10.23M	13.38M	9.71M	9.96M
Stockholders Equity	17.83M	17.83M	17.83M	17.83M	17.83M
Cash Flow
Free Cash Flow	2.84M	5.77M	4.72M	9.08M	2.79M
Operating Cash Flow	3.15M	5.85M	4.86M	9.13M	2.89M
Investing Cash Flow	906.80K	989.98K	58.66K	111.63K	189.04K
Financing Cash Flow	―	-7.79M	―	―	―

MeVis Medical Solutions Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 24.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:M3V, the sentiment is Negative. The current price of 24.8 is below the 20-day moving average (MA) of 24.85, below the 50-day MA of 24.80, and above the 200-day MA of 24.72, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 48.96 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:M3V.

MeVis Medical Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
M3V	80 Outperform	€45.14M	10.49	24.14%	3.83%	-5.72%	-25.19%
0710	78 Outperform	$5.10B	12.98	8.79%	2.64%	24.98%	-17.75%
DRW3	68 Neutral	€1.15B	12.69	6.87%	3.00%	-0.03%	-14.15%
Sector *	63 Neutral	€5.96B	17.56	-2.83%	2.08%	0.47%	-41.02%
FME	63 Neutral	€12.07B	18.39	4.83%	3.50%	0.53%	23.79%
BIO3	60 Neutral	€1.42B	44.96	-4.72%	0.13%	-18.82%	-113.85%
SRT3	50 Neutral	€11.40B	120.04	3.88%	0.41%	3.80%	33.31%